Trial Profile

A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camptothecin (Primary) ; Paclitaxel
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions
Sponsors Cerulean Pharma; New Links Genetics Corporation

Most Recent Events

31 Dec 2020 Results published in the Gynecologic Oncology
03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
02 Apr 2019 According to a NewLink Genetics Corporation media release, data from this study were presented at the American Association for Cancer Research (AACR) Annual Meeting 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com